P2RY12 and atrial fibrillation: The Randomized Evaluation of Dual Antithrombotic Therapy with Dabigatran versus Triple Therapy with Warfarin in Patients with Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (RE‐DUAL PCI) trial assessed the safety and efficacy of dabigatran dual therapy at doses of 110 or 150 mg with a P2Y12 inhibitor (either clopidogrel or ticagrelor) versus warfarin plus aspirin (ASA) and a P2Y12 inhibitor (either clopidogrel or ticagrelor) in patients with AF undergoing PCI.